Source-grounded facts extracted from Harvard Apparatus Regenerative Technology, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Harvard Apparatus Regenerative Technology, Inc. issued 411,765 shares of common stock of common stock to certain investors (the "Investors") for aggregate purchase price of approximately $0.7 million and a purchase price per share of $1.70.
“Investors agreed to purchase in a private placement an aggregate of 411,765 shares of common stock for the aggregate purchase price of approximately $0.7 million and a purchase price per share of $1.70”
Harvard Apparatus Regenerative Technology, Inc. entered into Purchase Agreement with certain investors valued at aggregate of 411,765 shares of common stock for the aggregate purchase price of approximately $0.7 m (effective 2025-12-30).
“Harvard Apparatus Regenerative Technology, Inc. (the “Company”) entered into Securities Purchase Agreements (each a “Purchase Agreement”), each effective as of December 30, 2025, with certain investors (the “Investors”) pursuant to which the Investors agreed to purchase in a private placement an aggregate of 411,765 shares of common stock for the aggregate purchase price of approximately $0.7 million and a purchase price per share of $1.70 (the “Private Placement”).”
Harvard Apparatus Regenerative Technology, Inc. engaged CBIZ CPAs P.C. as its auditor.
“the Registrant, with the approval of the Audit Committee of the Registrant’s Board of Directors, engaged CBIZ CPAs P.C. as the Registrant’s independent registered public accounting firm.”
Marcum LLP resigned as auditor of Harvard Apparatus Regenerative Technology, Inc..
“Marcum informed Harvard Apparatus Regenerative Technology, Inc. (the “Registrant”) that Marcum resigned as the Registrant’s independent registered public accounting firm.”
Mao Zhang was appointed as Class I Director at Harvard Apparatus Regenerative Technology, Inc..
“On August 26, 2024, Mao Zhang, the Founder and Chief Executive Officer of Stellars Capital, joined the Board of Directors (the “Board”) of the Company as a Class I director.”
Harvard Apparatus Regenerative Technology, Inc. entered into Securities Purchase Agreements with certain investors valued at $1.5 million (effective 2024-04-15).
“On April 15, 2024, Harvard Apparatus Regenerative Technology, Inc. (the “Company”) entered into Securities Purchase Agreements (each a “Purchase Agreement”) with certain investors (the “Investors”) pursuant to which the Investors agreed to purchase in a private placement an aggregate of 367,767 shares of common stock for the aggregate purchase price of $1.5 million and a purchase price per unit of $4.03 (the “Private Placement”).”
Harvard Apparatus Regenerative Technology, Inc. incurred loan of $500,000 with Junli He at 8% maturing on the earlier to occur of a) the closing date (or later date of capital being provided pertaining to such continued offering that the following threshold is tr.
“On February 1, 2024, Harvard Apparatus Regenerative Technology, Inc. (the “ Company ”) entered into a loan arrangement with Junli He, the Chairman and Chief Executive Officer of the Company (the “ Lender ”), pursuant to which the Lender has agreed to loan the Company an aggregate amount of $500,000 as evidenced by a Bridge Note executed by the Company in favor of, and accepted by, the Lender (the “ Bridge Note ”).”
Harvard Apparatus Regenerative Technology, Inc. entered into Bridge Note with Junli He valued at $500,000 (effective 2024-02-01).
“On February 1, 2024, Harvard Apparatus Regenerative Technology, Inc. (the “ Company ”) entered into a loan arrangement with Junli He, the Chairman and Chief Executive Officer of the Company (the “ Lender ”), pursuant to which the Lender has agreed to loan the Company an aggregate amount of $500,000 as evidenced by a Bridge Note executed by the Company in favor of, and accepted by, the Lender (the “ Bridge Note ”).”
Harvard Apparatus Regenerative Technology, Inc.: Amended and restated Bylaws solely to reflect the name change to Harvard Apparatus Regenerative Technology, Inc (effective 2023-07-20).
“The Company also amended and restated its Amended and Restated Bylaws, solely to reflect the name change (as amended, the “Third Amended and Restated Bylaws”). The Certificate of Amendment and the Third Amended and Restated Bylaws each became effective on July 20, 2023.”
Harvard Apparatus Regenerative Technology, Inc.: Amended Certificate of Incorporation to change company name from Biostage, Inc. to Harvard Apparatus Regenerative Technology, Inc (effective 2023-07-20).
“Harvard Apparatus Regenerative Technology, Inc. (the “Company”) filed an amendment (the “Certificate of Amendment”) to its Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) with the Secretary of State for the State of Delaware to change its name from Biostage, Inc. to Harvard Apparatus Regenerative Technology, Inc. The Company also amended and restated its Amended and Restated Bylaws, solely to reflect the name change (as amended, the “Third Amended and Restated Bylaws”). The Certificate of Amendment and the Third Amended and Restated Bylaws each became effective on July 20, 2023.”
Harvard Apparatus Regenerative Technology, Inc. shareholders approved Non-binding approval of the compensation of the Company’s named executive officers at the 2023-07-19 meeting.
“Proposal 4 – Approval, by Non-Binding Advisory Vote, of the Compensation of the Company’s Named Executive Officers The compensation of the Company’s named executive officers was approved, by a non-binding advisory vote, as follows: Votes Non-Votes 10,184,823 12,603 189,379 0”
Harvard Apparatus Regenerative Technology, Inc. shareholders approved Approval of the amendment to the Company’s Amended and Restated Equity Incentive Plan to increase the number of shares of common stock available for issuance pursuant thereto by 4,000,000 shares at the 2023-07-19 meeting.
“Proposal 3 – Approval of the amendment to the Company’s Amended and Restated Equity Incentive Plan The amendment to the Company’s Amended and Restated Equity Incentive Plan was approved as follows: Votes Non-Votes 10,370,321 16,358 126 0”
Harvard Apparatus Regenerative Technology, Inc. shareholders approved Ratification of the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-07-19 meeting.
“Proposal 2 – Ratification of the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 The ratification of the appointment of Marcum LLP as the Company’s independent registered public accounting firm was approved as follows: Votes Non-Votes 11,763,540 5,174 473 0”
Harvard Apparatus Regenerative Technology, Inc. shareholders approved Election of Directors at the 2023-07-19 meeting.
“Proposal 1 - Election of Directors On such election of directors proposal, each of Junli He and Dr. James Shmerling were elected as Class I Directors, each for a three-year term, such term to continue until the annual meeting of stockholders in 2026 and until such Director’s successor is duly elected and qualified or until their earlier resignation or removal. Due to the plurality election, votes could only be cast in favor of or withheld from the nominee and thus votes against were not applicable. The results of the election were as follows: Name Votes Withheld Broker Non-Votes Junli He 10,377,115 9,690 1,382,382 James Shmerling 2,345,415 8,041,390 1,382,382”
Ron Packard was appointed as Class II Director at Harvard Apparatus Regenerative Technology, Inc..
“On April 5, 2023, Ron Packard, the Chief Executive officer of Pansophic Learning, joined the Board of Directors (the “Board”) of the Company as a Class II director.”
Harvard Apparatus Regenerative Technology, Inc. entered into Securities Purchase Agreements with certain investors valued at $6 million (effective 2023-03-31).
“On March 31, 2023, Biostage, Inc. (the “Company”) entered into Securities Purchase Agreements (each a “Purchase Agreement”) with certain investors (the “Investors”) pursuant to which the Investors agreed to purchase in a private placement an aggregate of 1,000,967 shares of common stock for the aggregate purchase price of $6 million and a purchase price per unit of $6.00 (the “Private Placement”).”
David Green changed role as Chairman and Chief Executive Officer at Harvard Apparatus Regenerative Technology, Inc..
“the Company’s existing director, Junli (Jerry) He, was appointed Chairman and Chief Executive Officer of the Company, in replacement of David Green in such roles.”
Junli (Jerry) He was appointed as Chairman and Chief Executive Officer at Harvard Apparatus Regenerative Technology, Inc..
“the Company’s existing director, Junli (Jerry) He, was appointed Chairman and Chief Executive Officer of the Company, in replacement of David Green in such roles.”
David Green resigned as Chairman and Chief Executive Officer at Harvard Apparatus Regenerative Technology, Inc..
“in replacement of David Green in such roles.”
Junli (Jerry) He was appointed as Chairman and Chief Executive Officer at Harvard Apparatus Regenerative Technology, Inc..
“Junli (Jerry) He, was appointed Chairman and Chief Executive Officer of the Company, in replacement of David Green in such roles.”
David Green changed role as Chief Executive Officer at Harvard Apparatus Regenerative Technology, Inc..
“Effective as of January 11, 2023, Biostage, Inc. (the Company) entered into an Amended and Restated Employment Agreement (the Amended Agreement) with David Green, the Chief Executive Officer of the Company, to remove the Interim designation from his Chief Executive Officer title effective immediately”
Harvard Apparatus Regenerative Technology, Inc. reported the three months ended September 30, 2022 results: net income a net loss of approximately $1.1 million, EPS $0.10 per share.
“For the three months ended September 30, 2022, the Company reported a net loss of approximately $1.1 million, or $0.10 per share, compared to a net loss of $0.8 million, or $0.08 per share, for the three months ended September 30, 2021.”
Joseph L. Damasio, Jr. was appointed as Chief Financial Officer at Harvard Apparatus Regenerative Technology, Inc..
“Effective as of August 8, 2022, Biostage, Inc. (the Company) appointed Joseph L. Damasio, Jr., as Chief Financial Officer.”
Jason Chen was appointed as Vice Chairman of the Board at Harvard Apparatus Regenerative Technology, Inc..
“the Company’s existing Chairman, Jason Chen, was appointed Vice Chairman of the Board.”
David Green was appointed as Chairman of the Board at Harvard Apparatus Regenerative Technology, Inc..
“Mr. Green also joined the Board as a Class II director and was appointed Chairman of the Board.”
David Green was appointed as Interim Chief Executive Officer at Harvard Apparatus Regenerative Technology, Inc..
“Effective as of November 26, 2021, the Company appointed Mr. Green as Interim Chief Executive Officer.”
Junli He was appointed as Class I director at Harvard Apparatus Regenerative Technology, Inc..
“On September 1, 2021, Junli He, the Executive Vice Chairman of Bright Scholar Holdings, joined the Board of Directors (the “Board”) of the Company as a Class I director.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.